Zanamivir Susceptibility Monitoring and Characterization of Influenza Virus Clinical Isolates Obtained during Phase II Clinical Efficacy Studies

Zanamivir is a highly selective neuraminidase (NA) inhibitor with demonstrated clinical efficacy against influenza A and B virus infections. In phase II clinical efficacy trials (NAIB2005 and NAIB2008), virological substudies showed mean reductions in virus shedding after 24 h of treatment of 1.5 to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Barnett, J. M., Cadman, A., Gor, D., Dempsey, M., Walters, M., Candlin, A., Tisdale, M., Morley, P. J., Owens, I. J., Fenton, R. J., Lewis, A. P., Claas, E. C. J., Rimmelzwaan, G. F., De Groot, R., Osterhaus, A. D. M. E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2000
Schlagworte:
Antiviral Agents
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC89632/
https://ncbi.nlm.nih.gov/pubmed/10602727
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge